What is Qure.ai?
Qure.ai is a specialized healthtech enterprise dedicated to enhancing clinical decision-making through sophisticated AI-driven medical imaging solutions. The company focuses on the early detection and management of critical health conditions, including lung cancer, tuberculosis, and stroke. By integrating seamlessly into existing clinical workflows, Qure.ai provides healthcare professionals with actionable, real-time data that significantly improves patient outcomes. With a presence in over 90 countries and an impact spanning more than 25 million lives, the company has established itself as a critical infrastructure provider in the global healthcare ecosystem, bridging the gap between complex diagnostic needs and accessible, timely medical assistance.
How much funding has Qure.ai raised?
Qure.ai has raised a total of $125.3M across 4 funding rounds:
Unspecified
$16M
Grant
$4.3M
Other Financing Round
$40M
Series D
$65M
Unspecified (2020): $16M with participation from MassMutual Ventures Southeast Asia and Sequoia India
Grant (2022): $4.3M led by SBRI Healthcare
Other Financing Round (2022): $40M supported by Massachusetts Mutual Life Insurance, Novo Holdings, and HealthQuad
Series D (2024): $65M featuring Merck Global Health Innovation Fund, Lightspeed, and Kae Capital
Key Investors in Qure.ai
Merck Global Health Innovation Fund
Merck Global Health Innovation Fund is a growth-oriented investor that partners with digital health and data science companies to optimize biopharmaceutical operations and improve patient care.
Lightspeed
Lightspeed is a global technology firm providing cloud-based software and payment solutions that enable businesses to manage operations and scale effectively across multiple locations.
Kae Capital
Kae Capital is a pioneer of early-stage investing in India, specializing in supporting tech startups with industry connections and capital to build enduring global companies.
What's next for Qure.ai?
With the successful closure of this major strategic investment, Qure.ai is poised to accelerate its research and development initiatives, focusing on the next generation of diagnostic accuracy and predictive analytics. The company is expected to prioritize the scaling of its AI tools to reach even more underserved communities, while simultaneously strengthening its partnerships with global health organizations and biopharmaceutical entities. As the healthcare industry increasingly shifts toward data-centric, preventative care models, Qure.ai is well-positioned to lead the market, leveraging its substantial financial backing to maintain its competitive edge in the rapidly evolving medical imaging landscape.
See full Qure.ai company page
